Findings in a recent analysis reports have subjected that the anti-thrombotic inhibitor, Vorapaxar, which was shadowed by bleeding concerns, has been found to be beneficiary for those who have been suffering from myocardial infarction (MI) since a long time.

Those of the patients with a history of MI, 8,898 were randomly given the vorapaxar. It was found that the group witnessed less cardiovascular deaths or due to heart attack or stroke, in comparison to 8,881 patients who were given placebo.

According to Benjamin M. Scirica, MD, of Brigham and Women's Hospital in Boston, and colleagues, "Although the rate of moderate or severe bleeding was significantly higher in the vorapaxar group, the rate of intracranial hemorrhage was not significantly different from the placebo group".

They added that those of the patients, who were below the age of 75 and had never, suffered a stroke before or transient ischemic attack and their weight accounted for at least 132 lbs were the ones, who gained the most benefit of the drug, manufactured by Merck and Co.

Sunday, the company announced that they are aiming at achieving an approval from the regulatory bodies of US and Europe for the sale of the drug and another cardiovascular drug in 2013. Study researchers suggest that the benefits of the drug will outweigh its disadvantages.